Literature DB >> 1083340

Methotrexate resistance and uptake of DDMP by L5178Y cells. Selective protection with folinic acid.

B T Hill, L A Price, J H Goldie, S I Harrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1083340     DOI： 10.1016/0014-2964(75)90126-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  6 in total

1.  Initial clinical experience with a simultaneous combination of 2,4-diamino-5(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) with folinic acid.

Authors:  P Alberto; R Peytremann; R Medenica; M Beretta-Piccoli
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).

Authors:  R de Jager; D Dupont; J J Rodzynek; C Dorlet; G Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Phase II clinical trial of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors.

Authors:  R de Jager; A Brugarolas; M Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 4.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.